Beta-blockade With Landiolol in Out-of-hospital Cardiac Arrest

Last updated: March 16, 2023
Sponsor: Medical University of Vienna
Overall Status: Active - Recruiting

Phase

1/2

Condition

Heart Attack (Myocardial Infarction)

Heart Failure

Circulation Disorders

Treatment

N/A

Clinical Study ID

NCT05554978
Beta Blockade Cardiac Arrest
  • Ages 18-85
  • All Genders

Study Summary

This study investigates the efficacy of landiolol versus placebo in patients with out-of-hospital cardiac arrest (OHCA) and refractory ventricular fibrillation (electrical storm).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • OHCA , >/=18 years of age
  • 3 or more shockable rhythms (VF or pVT) and last rhythm shockable

Exclusion

Exclusion Criteria:

  • Age > 85a
  • Severe head trauma or acute active bleeding
  • Known allergy or insensitivity to landiolol or another beta-blocker

Study Design

Total Participants: 32
Study Start date:
March 03, 2021
Estimated Completion Date:
December 31, 2023

Study Description

The use of beta-blockers in OHCA patients with refractory VF could potentially reverse the unwanted beta-1-mediated effects of endogenous and exogenous epinephrine (proarrhythmic effect), which could in turn lead to a shorter time until return of spontaneous circulation (ROSC).

This is a prospective, double-blind, randomized placebo-controlled pilot trial. The investigators consider this a pilot trial, as this is the first prospective trial evaluating the use of beta-blockade in cardiac arrest.

Connect with a study center

  • Medical University of Vienna

    Vienna,
    Austria

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.